Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00326248 · ClinicalTrials.gov registry record · Phase 3
Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 482
- Enrollment target
NCT00326248 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 482 participants.
The verdict
NCT00326248, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 482 participants
- Enrollment target
Study Summary
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
Interventions
- DRUG GW679769 (casopitant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 482 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00326248
The ClinicalTrials.gov registry entry for NCT00326248 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 482 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW679769 (casopitant) is the first listed.
NCT00326248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00326248 about?
NCT00326248 is a clinical study titled "Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women". This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
What is the current status of trial NCT00326248?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 482 participants. The study started on 2006-03. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00326248?
The interventions under investigation include: GW679769 (casopitant) (DRUG).
Who is sponsoring clinical trial NCT00326248?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.